Go Pro
→ Porter flew 3,300 miles to investigate this system (From Porter & Company) (Ad)tc pixel

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Compare
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Monte Rosa Therapeutics, Inc. stock logo
GLUE
Monte Rosa Therapeutics
$14.22
-0.6%		$19.36
$4.78
▼
$25.77
$1.22B1.51.03 million shs1.53 million shs
MoonLake Immunotherapeutics stock logo
MLTX
MoonLake Immunotherapeutics
$15.06
-0.5%		$17.99
$5.95
▼
$62.75
$1.29B1.041.35 million shs1.19 million shs
ODTX
Odyssey Therapeutics
$26.62
+8.7%		$20.08
$15.10
▼
$28.00
$1.18BN/A151,851 shs171,403 shs
YD Bio Limited stock logo
YDES
YD Bio
$3.76
-0.5%		$2.79
$1.70
▼
$25.00
$267.23MN/A88,808 shs567,647 shs
7 Energy Stocks to Buy and Hold Forever Cover
7 Energy Stocks to Buy and Hold Forever

With the proliferation of data centers and electric vehicles, the electric grid will only get more strained. Download this report to learn how energy stocks can play a role in your portfolio as the global demand for energy continues to grow.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Monte Rosa Therapeutics, Inc. stock logo
GLUE
Monte Rosa Therapeutics
-0.63%-1.11%-7.54%-18.09%+189.02%
MoonLake Immunotherapeutics stock logo
MLTX
MoonLake Immunotherapeutics
-0.46%-3.59%-13.45%-19.55%-74.28%
ODTX
Odyssey Therapeutics
+8.65%+3.90%+46.83%+56.59%+2,661,999,900.00%
YD Bio Limited stock logo
YDES
YD Bio
-0.53%-13.36%+63.48%+19.75%+375,999,900.00%
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Monte Rosa Therapeutics, Inc. stock logo
GLUE
Monte Rosa Therapeutics
$14.22
-0.6%		$19.36
$4.78
▼
$25.77
$1.22B1.51.03 million shs1.53 million shs
MoonLake Immunotherapeutics stock logo
MLTX
MoonLake Immunotherapeutics
$15.06
-0.5%		$17.99
$5.95
▼
$62.75
$1.29B1.041.35 million shs1.19 million shs
ODTX
Odyssey Therapeutics
$26.62
+8.7%		$20.08
$15.10
▼
$28.00
$1.18BN/A151,851 shs171,403 shs
YD Bio Limited stock logo
YDES
YD Bio
$3.76
-0.5%		$2.79
$1.70
▼
$25.00
$267.23MN/A88,808 shs567,647 shs
7 Energy Stocks to Buy and Hold Forever Cover
7 Energy Stocks to Buy and Hold Forever

With the proliferation of data centers and electric vehicles, the electric grid will only get more strained. Download this report to learn how energy stocks can play a role in your portfolio as the global demand for energy continues to grow.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Monte Rosa Therapeutics, Inc. stock logo
GLUE
Monte Rosa Therapeutics
-0.63%-1.11%-7.54%-18.09%+189.02%
MoonLake Immunotherapeutics stock logo
MLTX
MoonLake Immunotherapeutics
-0.46%-3.59%-13.45%-19.55%-74.28%
ODTX
Odyssey Therapeutics
+8.65%+3.90%+46.83%+56.59%+2,661,999,900.00%
YD Bio Limited stock logo
YDES
YD Bio
-0.53%-13.36%+63.48%+19.75%+375,999,900.00%
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Monte Rosa Therapeutics, Inc. stock logo
GLUE
Monte Rosa Therapeutics
2.78
Moderate Buy$28.50100.42% Upside
MoonLake Immunotherapeutics stock logo
MLTX
MoonLake Immunotherapeutics
2.41
Hold$24.5763.16% Upside
ODTX
Odyssey Therapeutics
2.63
Moderate Buy$35.7534.30% Upside
YD Bio Limited stock logo
YDES
YD Bio
1.00
SellN/AN/A

Current Analyst Ratings Breakdown

Latest YDES, MLTX, ODTX, and GLUE Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
8/27/2026
ODTX
Odyssey Therapeutics
HC Wainwright logo
HC Wainwright
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Initiated CoverageBuy$44.00
8/27/2026
ODTX
Odyssey Therapeutics
HC Wainwright logo
HC Wainwright
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Initiated CoverageBuy$44.00
8/25/2026
Monte Rosa Therapeutics, Inc. stock logo
GLUE
Monte Rosa Therapeutics
Guggenheim logo
Guggenheim
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingBuy$28.00
8/24/2026
Monte Rosa Therapeutics, Inc. stock logo
GLUE
Monte Rosa Therapeutics
TD Cowen logo
TD Cowen
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
UpgradeStrong-Buy
8/21/2026
MoonLake Immunotherapeutics stock logo
MLTX
MoonLake Immunotherapeutics
Weiss Ratings logo
Weiss Ratings
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
UpgradeSell (E+) ➝ Sell (D-)
8/13/2026
MoonLake Immunotherapeutics stock logo
MLTX
MoonLake Immunotherapeutics
HC Wainwright logo
HC Wainwright
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Boost Price TargetBuy$45.00 ➝ $50.00
8/11/2026
Monte Rosa Therapeutics, Inc. stock logo
GLUE
Monte Rosa Therapeutics
Weiss Ratings logo
Weiss Ratings
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
DowngradeSell (D+) ➝ Sell (D)
8/11/2026
ODTX
Odyssey Therapeutics
Weiss Ratings logo
Weiss Ratings
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Initiated CoverageSell (D+)
8/7/2026
MoonLake Immunotherapeutics stock logo
MLTX
MoonLake Immunotherapeutics
Weiss Ratings logo
Weiss Ratings
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingSell (E+)
8/7/2026
Monte Rosa Therapeutics, Inc. stock logo
GLUE
Monte Rosa Therapeutics
Guggenheim logo
Guggenheim
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Lower Price TargetBuy$35.00 ➝ $28.00
8/7/2026
Monte Rosa Therapeutics, Inc. stock logo
GLUE
Monte Rosa Therapeutics
JPMorgan Chase & Co. logo
JPMorgan Chase & Co.
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Lower Price TargetOverweight$31.00 ➝ $27.00
(Data available from 9/3/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Monte Rosa Therapeutics, Inc. stock logo
GLUE
Monte Rosa Therapeutics
$28.73M42.23N/AN/A$5.71 per share2.49
MoonLake Immunotherapeutics stock logo
MLTX
MoonLake Immunotherapeutics
N/AN/AN/AN/A$5.03 per shareN/A
ODTX
Odyssey Therapeutics
N/AN/AN/AN/A$8.76 per shareN/A
YD Bio Limited stock logo
YDES
YD Bio
N/AN/AN/AN/AN/AN/A
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Monte Rosa Therapeutics, Inc. stock logo
GLUE
Monte Rosa Therapeutics
-$38.63M-$1.76N/AN/AN/A-560.85%-43.31%-27.59%11/5/2026 (Estimated)
MoonLake Immunotherapeutics stock logo
MLTX
MoonLake Immunotherapeutics
-$227.32M-$3.84N/AN/AN/AN/A-82.53%-58.17%11/4/2026 (Estimated)
ODTX
Odyssey Therapeutics
N/A-$6.77N/AN/AN/AN/AN/AN/AN/A
YD Bio Limited stock logo
YDES
YD Bio
N/AN/AN/AN/AN/AN/AN/AN/AN/A

Latest YDES, MLTX, ODTX, and GLUE Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
8/10/2026Q2 2026
MoonLake Immunotherapeutics stock logo
MLTX
MoonLake Immunotherapeutics
-$0.9086-$0.84+$0.0686-$0.84N/AN/A
8/6/2026Q2 2026
Monte Rosa Therapeutics, Inc. stock logo
GLUE
Monte Rosa Therapeutics
-$0.3805-$0.43-$0.0495-$0.43$12.91 million$8.97 million
8/5/2026Q2 2026
ODTX
Odyssey Therapeutics
N/A-$1.74N/A-$1.74N/AN/A
6/17/2026Q1 2026
ODTX
Odyssey Therapeutics
-$1.31-$6.77-$5.46-$6.77N/AN/A
CompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive Growth
Monte Rosa Therapeutics, Inc. stock logo
GLUE
Monte Rosa Therapeutics
N/AN/AN/AN/AN/A
MoonLake Immunotherapeutics stock logo
MLTX
MoonLake Immunotherapeutics
N/AN/AN/AN/AN/A
ODTX
Odyssey Therapeutics
N/AN/AN/AN/AN/A
YD Bio Limited stock logo
YDES
YD Bio
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Monte Rosa Therapeutics, Inc. stock logo
GLUE
Monte Rosa Therapeutics
N/A
10.58
10.58
MoonLake Immunotherapeutics stock logo
MLTX
MoonLake Immunotherapeutics
0.23
12.56
12.56
ODTX
Odyssey Therapeutics
N/A
11.36
11.36
YD Bio Limited stock logo
YDES
YD Bio
N/AN/AN/A

Institutional Ownership

CompanyInstitutional Ownership
Monte Rosa Therapeutics, Inc. stock logo
GLUE
Monte Rosa Therapeutics
79.96%
MoonLake Immunotherapeutics stock logo
MLTX
MoonLake Immunotherapeutics
93.85%
ODTX
Odyssey Therapeutics
N/A
YD Bio Limited stock logo
YDES
YD Bio
N/A

Insider Ownership

CompanyInsider Ownership
Monte Rosa Therapeutics, Inc. stock logo
GLUE
Monte Rosa Therapeutics
6.40%
MoonLake Immunotherapeutics stock logo
MLTX
MoonLake Immunotherapeutics
10.40%
ODTX
Odyssey Therapeutics
N/A
YD Bio Limited stock logo
YDES
YD Bio
N/A
CompanyEmployeesShares OutstandingFree FloatOptionable
Monte Rosa Therapeutics, Inc. stock logo
GLUE
Monte Rosa Therapeutics
9085.31 million79.85 millionOptionable
MoonLake Immunotherapeutics stock logo
MLTX
MoonLake Immunotherapeutics
285.11 million76.26 millionOptionable
ODTX
Odyssey Therapeutics
N/A48.06 millionN/AN/A
YD Bio Limited stock logo
YDES
YD Bio
N/A70.79 millionN/AN/A

Recent News About These Companies

中概股跌幅榜前十，YD Bio Limited(YDES.US)跌22.71%，房多多(DUO.US)跌20.85%
September 1 at 6:15 PM  |  finet.hkF
YD Bio Ltd (YDES)
September 1 at 7:24 AM  |  finance.yahoo.comhttps://finance.yahoo.com/quote/YDES/news/
YD Bio Files First-Half 2026 Results, Reports Improved Equity Position
September 1 at 6:50 AM  |  tipranks.comhttps://www.tipranks.com/news/company-announcements/yd-bio-files-first-half-2026-results-reports-improved-equity-position?utm_source=marketbeat.com&utm_medium=referral
YD Bio Limited Reports First-Half 2026 Financial Results, 315% Revenue Growth and Net Income of $6.7 Million
August 31 at 6:10 PM  |  quiverquant.comQ
YD Bio Limited Reports Unaudited Financial Results for the Six Months Ended June 30, 2026
August 31 at 6:00 PM  |  globenewswire.comhttps://www.globenewswire.com/news-release/2026/08/31/3353740/0/en/yd-bio-limited-reports-unaudited-financial-results-for-the-six-months-ended-june-30-2026.html
YDES - YD Bio Limited
August 26, 2026  |  seekingalpha.comhttps://seekingalpha.com/symbol/YDES/historical-price-quotes
Yd Bio Limited publie un article de revue évalué par les pairs dans Nutrients et lance deux produits nutraceutiques à Taïwan
August 26, 2026  |  zonebourse.comZ
YD Bio Announces Peer-Reviewed Publication in Nutrients, Co-Authored with Physicians from the Taiwan Chronic Disease Healthcare Association and the Future Health Institute
August 25, 2026  |  globenewswire.comhttps://www.globenewswire.com/news-release/2026/08/25/3350403/0/en/yd-bio-announces-peer-reviewed-publication-in-nutrients-co-authored-with-physicians-from-the-taiwan-chronic-disease-healthcare-association-and-the-future-health-institute.html
YD Bio Launches a Physician-Partnership Initiative in Taiwan with the Announcement of Two Nutraceutical Products in Collaboration with the Taiwan Chronic Disease Healthcare ...
August 11, 2026  |  markets.businessinsider.comhttps://markets.businessinsider.com/news/stocks/yd-bio-launches-a-physician-partnership-initiative-in-taiwan-with-the-announcement-of-two-nutraceutical-products-in-collaboration-with-the-taiwan-chronic-disease-healthcare-association-and-the-1036440665
YD Bio Launches Physician-Led Nutraceuticals in Taiwan to Build Consumer Health Ecosystem
August 11, 2026  |  tipranks.comhttps://www.tipranks.com/news/company-announcements/yd-bio-launches-physician-led-nutraceuticals-in-taiwan-to-build-consumer-health-ecosystem?utm_source=marketbeat.com&utm_medium=referral
YD Bio Highlights Peer-Reviewed Publication on New Computational Framework for Keratoconus Research
August 4, 2026  |  markets.businessinsider.comhttps://markets.businessinsider.com/news/stocks/yd-bio-highlights-peer-reviewed-publication-on-new-computational-framework-for-keratoconus-research-1036405738
YD Bio Launches Cross-Border Cancer Testing Pilot with Numia Health to Evaluate Expanded Access to Molecular Diagnostics in Canada
July 28, 2026  |  finance.yahoo.comhttps://finance.yahoo.com/healthcare/articles/yd-bio-launches-cross-border-120000068.html
YD Bio and EG BioMed Conclude Successful Exhibition at BIO Asia-Taiwan 2026, Highlighting Innovations in Ophthalmology, Oncology Diagnostics, and Clinical Services
July 24, 2026  |  markets.businessinsider.comhttps://markets.businessinsider.com/news/stocks/yd-bio-and-eg-biomed-conclude-successful-exhibition-at-bio-asia-taiwan-2026-highlighting-innovations-in-ophthalmology-oncology-diagnostics-and-clinical-services-1036356738
YD Bio Limited
July 15, 2026  |  cnn.comhttps://www.cnn.com/markets/stocks/YDES
YD Bio Limited Ordinary Shares (YDES) Insider Activity
July 14, 2026  |  nasdaq.comhttps://www.nasdaq.com/market-activity/stocks/ydes/insider-activity
YD Bio Expands U.S. Laboratory Footprint to 46 States, Strengthening DNA-Methylation Early Cancer Detection Operations
July 2, 2026  |  globenewswire.comhttps://www.globenewswire.com/news-release/2026/07/02/3321265/0/en/yd-bio-expands-u-s-laboratory-footprint-to-46-states-strengthening-dna-methylation-early-cancer-detection-operations.html
YD Bio Ltd.
June 25, 2026  |  barrons.comhttps://www.barrons.com/market-data/stocks/ydes/research-ratings
Yd Bio
June 25, 2026  |  fool.comhttps://www.fool.com/quote/nasdaq/ydes/
YD Bio Analyst Ratings and Price Targets | NASDAQ:YDES | Benzinga
June 25, 2026  |  benzinga.comhttps://www.benzinga.com/quote/YDES/analyst-ratings
YD Bio Limited Reports Financial Results for Full Year 2025, Achieves 17% Revenue Growth and Strategic Advances in Healthcare Innovations
April 30, 2026  |  quiverquant.comQ

New MarketBeat Followers Over Time

Media Sentiment Over Time

Monte Rosa Therapeutics stock logo

Monte Rosa Therapeutics NASDAQ:GLUE

$14.22 -0.09 (-0.63%)
Closing price 09/2/2026 04:00 PM Eastern
Extended Trading
$14.61 +0.39 (+2.74%)
As of 09/2/2026 07:30 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Monte Rosa Therapeutics, Inc., a clinical-stage biotechnology company, engages in the development of novel small molecule precision medicines that employ the body's natural mechanisms to selectively degrade therapeutically relevant proteins. The company develops MRT-2359, an orally bioavailable molecular glue degrader targeting the translation termination factor protein GSPT1 for the treatment of MYC-driven tumors; MRT-6160 for the treatment of systemic and central nervous system autoimmune diseases; and MRT-8102 for the treatment of IL-1?/NLRP3 driven inflammatory diseases. It also develops CDK2 to treat ovarian, uterine, and breast cancers. The company was incorporated in 2019 and is headquartered in Boston, Massachusetts.

MoonLake Immunotherapeutics stock logo

MoonLake Immunotherapeutics NASDAQ:MLTX

$15.06 -0.07 (-0.46%)
Closing price 09/2/2026 04:00 PM Eastern
Extended Trading
$14.98 -0.08 (-0.52%)
As of 09/2/2026 07:57 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

MoonLake Immunotherapeutics, a clinical-stage biopharmaceutical company, engages in developing therapies. It develops Sonelokimab, a novel investigational Nanobody for the treatment of inflammation diseases; and hidradenitis suppurativa, psoriatic arthritis, axial spondyloarthritis, and psoriasis. MoonLake Immunotherapeutics was incorporated in 2020 and is headquartered in Zug, Switzerland.

Odyssey Therapeutics NASDAQ:ODTX

$26.62 +2.12 (+8.65%)
As of 09/2/2026 04:00 PM Eastern

Odyssey Therapeutics Inc. is a clinical-stage biopharmaceutical company seeking to transform the standard of care for patients suffering from autoimmune and inflammatory diseases by developing medicines which are designed to precisely target disease pathology. Odyssey Therapeutics Inc. is based in BOSTON.

YD Bio stock logo

YD Bio NASDAQ:YDES

$3.76 -0.02 (-0.53%)
Closing price 09/2/2026 04:00 PM Eastern
Extended Trading
$3.86 +0.10 (+2.66%)
As of 09/2/2026 07:58 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

YD Bio Limited is a biotechnology company advancing DNA methylation-based cancer detection technology and ophthalmologic innovations.

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

Stock Lists
Low Priced Stocks
Stocks By Exchange
Latest Stock Ideas